Diagnostic Algorithm for Secondary Extramammary Paget Disease from Institutional Cases and Literature Review
Cancers · 17.12.2025 · 17 (24) · 4014
DOI: 10.3390/cancers17244014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.12.2025. Verfasst von Salin Kiratikanon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Although clinicopathologic correlation with integration of clinical and radiographic data is the gold standard in distinguishing primary extramammary Paget disease (EMPD) from secondary EMPD, immunoprofiling of EMPD tumors enables distinction between primary and secondary EMPD.
Methods
We evaluated the immunoprofiles of previously published cases in the literature as well as 12 secondary EMPD cases from our archives in order to construct a diagnostic algorithm that enables the distinction between primary and secondary EMPD.
Results
Immunoprofiles of 480 primary (published cases) and 132 secondary (120 published cases and 12 institutional cases) EMPD cases were compared. CK7, CK20, CDX2, GATA3, GCDFP15, TRPS1, and SATB2 expression was significantly different in primary EMPD versus colonic secondary EMPD (p < 0.001 for all except SATB2, p = 0.036). CK20, GCDFP15, TRPS1, p63 and uroplakin II/III expression was significantly different in primary EMPD versus urothelial secondary EMPD (p < 0.001). CK7, CDX2, SATB2, GATA3 and p63 expression was significantly different in colonic versus urothelial secondary EMPD. CK20, CDX2, and GCDFP15 expression was significantly different in colonic versus prostatic secondary EMPD. CK20 expression was significantly different in colonic versus prostatic secondary EMPD (p = 0.018). CK20, GCDFP15 and TRPS1 are helpful in the distinction of primary EMPD versus colonic and urothelial secondary EMPD (p < 0.001).
Conclusions
We propose that the initial IHC panel should include TRPS1, CK7 and CK20. In TRPS1-negative cases, additional immunostains should be performed: CDX2 and SATB2 for colonic; p63, GATA3 and uroplakin II/III for urothelial; and PSA and NKX3.1 for prostatic secondary EMPD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto 606-8507, Japan.
- Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Salin Kiratikanon, Ayaka Fukui, Masahiro Hirata, Jakob M T Moran, Masakazu Fujimoto, Mai P Hoang
Zitieren
APA
Kiratikanon, S., Fukui, A., Hirata, M., Moran, J. M. T., Fujimoto, M., & Hoang, M. P. (2025). Diagnostic Algorithm for Secondary Extramammary Paget Disease from Institutional Cases and Literature Review. Cancers, 17(24), 4014. https://doi.org/10.3390/cancers17244014
Vancouver
Kiratikanon S, Fukui A, Hirata M, Moran JMT, Fujimoto M, Hoang MP. Diagnostic Algorithm for Secondary Extramammary Paget Disease from Institutional Cases and Literature Review. Cancers. 2025;17(24):4014. doi:10.3390/cancers17244014
BibTeX
@article{Kiratikanon2025,
author = {Kiratikanon, Salin and Fukui, Ayaka and Hirata, Masahiro and Moran, Jakob M T and Fujimoto, Masakazu and Hoang, Mai P},
title = {Diagnostic Algorithm for Secondary Extramammary Paget Disease from Institutional Cases and Literature Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {24},
pages = {4014},
doi = {10.3390/cancers17244014}
}
EUVIMED